Form 4: Century Therapeutics Director Cynthia Butitta Granted 44,000 Stock Options

Cynthia M. Butitta, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.60, vesting over approximately one year.

Summary

• Cynthia M. Butitta, a Director of Century Therapeutics, Inc. (IPSC), was granted 44,000 stock options.
• The transaction occurred on June 12, 2025.
• The exercise price for these options is $0.60 per share.
• The options are exercisable immediately upon vesting and expire on June 12, 2035.
• Vesting occurs on the earlier of June 12, 2026, or the next annual meeting of stockholders, contingent on Ms. Butitta's continued service.
• Following this transaction, Ms. Butitta beneficially owns 44,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is generally viewed as a neutral to slightly positive event as it aligns interests. There are no negative operational or financial disclosures.

Positives

• The grant of stock options aligns the interests of Director Cynthia M. Butitta with those of shareholders, as the value of the options increases with the company's stock price.
• The vesting schedule, tied to continued service, incentivizes long-term commitment from a key board member.

Negatives

• The issuance of new stock options, if exercised, could lead to minor dilution for existing shareholders, although the amount (44,000 shares) is relatively small.

Risks

• The value of the stock options is dependent on the future market price of Century Therapeutics, Inc. common stock. If the stock price does not exceed the exercise price of $0.60, the options may expire worthless.
• The vesting of options is contingent on the director's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The stock options are subject to a vesting schedule, indicating that the full benefit of the grant is contingent on the director's continued service to the company until at least June 12, 2026, or the next annual meeting of stockholders. This structure aims to incentivize long-term commitment.

Management Comments

• While no direct quotes are provided, the filing indicates that Director Cynthia M. Butitta was granted 44,000 stock options as part of her compensation, aligning her interests with the company's performance.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a form of equity compensation to attract, retain, and incentivize board members by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• This is a standard equity grant for a director. Without specific details on Century Therapeutics' compensation philosophy or comparable grants at similar-sized biotech companies (e.g., those in early-stage clinical development or with similar market capitalization), a direct quantitative comparison is not feasible from this document alone. However, the structure (options with vesting) is consistent with typical industry compensation practices for non-employee directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also improved alignment of director's interests with shareholder value.
• Director (Cynthia M. Butitta): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the next annual meeting of stockholders, subject to continued service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 12, 2035.

Key Dates

Keywords

Century Therapeutics, IPSC, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting